Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2012 Net Income-$16.89M-$16.89MderivedN/M vs Q4 2012 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$16,673,000N/M Operating Cash Flowderived-$14,601,000N/M Free Cash Flowderived-$14,548,000— ended Dec 31, 2013 · filed Apr 1, 2014 · 91 d after period end